Summary
The product Trenbolone Acetate 100 mg/ml, manufactured by PrimePharma, was analyzed to verify its composition and potency. The sample, identified by batch number PP1778, was submitted by the reseller Opitropin.EU and tested by Janoshik Analytical, a laboratory known for its expertise in pharmaceutical quality testing. The analysis confirmed the presence of Trenbolone Acetate with a measured concentration of 95.91 mg/ml, reflecting a 4.09% variance from the label claim. These findings indicate that the product is accurately dosed within acceptable limits.
The testing process was initiated on 2 May 2023, with the sample received on 11 May 2023, and the analysis completed on 15 May 2023. Although the sample was procured and submitted by a reseller rather than the manufacturer, this does not entirely eliminate the potential for bias. Resellers may also selectively submit optimal batches or have other motivations that could influence the objectivity of the sample. This report serves an educational purpose, aiming to help consumers make informed decisions about the accuracy and consistency of anabolic steroid products.
Detailed Report
Product Overview
- Manufacturer: PrimePharma
- Product Name: Trenbolone Acetate 100 mg/ml
- Active Ingredient: Trenbolone Acetate
- Batch Number: PP1778
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #29393
- Testing Ordered: 2 May 2023
- Sample Received: 11 May 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 100 mg/ml (as stated on the label)
- Measured Concentration: 95.91 mg/ml
- Accuracy: 95.91% (4.09% below the label claim)
Verification Details:
- Verification URL: https://janoshik.com/tests/29393_ZW5E32SPVYSL
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This test report was submitted and funded by Opitropin.EU, a reseller rather than the product’s manufacturer. While reseller-submitted samples may provide a better representation of the market, they are not immune to potential bias. Resellers could also selectively choose batches they know are more likely to meet label claims, which may not reflect the consistency of the product available to consumers. The transparency and credibility of Janoshik Analytical, along with the measured concentration aligning closely with the product’s specification, lend confidence to the findings. However, cross-referencing with independent third-party testing is strongly encouraged to validate these results further.
Conclusion
The analysis demonstrates that Trenbolone Acetate 100 mg/ml from PrimePharma is slightly underdosed compared to its labeled specification but remains within acceptable limits. Although the sample was submitted by a reseller rather than the manufacturer, the potential for bias still warrants careful consideration. This report provides valuable insights for educational and harm reduction purposes, but independent validation would enhance confidence in the product’s consistency and quality.
Disclaimer: This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases, similar to manufacturer-funded testing. However, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.